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Abstract 
 
In cancer clinical trials where time-to-event outcome is the primary endpoint, almost 
routinely, the logrank test is prespecified as the primary test and the hazard ratio (HR) 
is used to quantify treatment effect. The methods for the logrank test and the estimation 
of the HR provide coherent results in terms of statistical significance, which is desirable 
property for treatment decision making from the reported results of the clinical trials. 
Statistical theory also supports that the logrank test offers the most power so long as the 
ratio of the two hazard functions is constant [i.e., proportional hazards (PH)], and it is 
a valid test even in non-PH. However, from clinical perspective, the lack of robustness 
and clinical interpretability of the estimation of the HR is not negligible as it is essential 
for investigators of clinical trials to provide a magnitude of the treatment effect that is 
helpful for treatment decision making. Also, the violation of the PH assumption has 
been seen in quite a few clinical trials in cancer, where the logrank test is not optimal 
anymore. Given these, the current routine practice using the logrank test for comparison 
and the HR for summarizing the magnitude of the treatment effect may be sub-optimal. 
The overarching goal of my research is improving routinely used test/estimation method. 
Specifically, in this thesis, we illustrate one of the issues of HR estimation when the PH 
assumption does not hold. We also develop and propose a novel test/estimation 
approach based on the difference in restricted mean survival time which has been 
extensively discussed in recent cancer clinical journals as an alternative summary 
measure to the HR. We conclude that the proposed approach is a useful analysis method 
for survival time data in cancer clinical trials from both of the statistical and clinical 
perspectives. 
